ATE493135T1 - Verfahren zur verhinderung von fibringerinnseln im lungengewebe durch verwendung von aerosolisierten gerinnungshemmern - Google Patents

Verfahren zur verhinderung von fibringerinnseln im lungengewebe durch verwendung von aerosolisierten gerinnungshemmern

Info

Publication number
ATE493135T1
ATE493135T1 AT05713495T AT05713495T ATE493135T1 AT E493135 T1 ATE493135 T1 AT E493135T1 AT 05713495 T AT05713495 T AT 05713495T AT 05713495 T AT05713495 T AT 05713495T AT E493135 T1 ATE493135 T1 AT E493135T1
Authority
AT
Austria
Prior art keywords
anticolotting
fibring
aerosolized
clots
agents
Prior art date
Application number
AT05713495T
Other languages
German (de)
English (en)
Inventor
Perenlei Enkhbaatar
Kazunori Murakami
Daniel Traber
Original Assignee
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas filed Critical Univ Texas
Application granted granted Critical
Publication of ATE493135T1 publication Critical patent/ATE493135T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT05713495T 2004-02-20 2005-02-15 Verfahren zur verhinderung von fibringerinnseln im lungengewebe durch verwendung von aerosolisierten gerinnungshemmern ATE493135T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US54623604P 2004-02-20 2004-02-20
US11/057,522 US20050192226A1 (en) 2004-02-20 2005-02-14 Method of preventing fibrin clots in pulmonary tissue through the use of aerosolized anticoagulants
PCT/US2005/004604 WO2005081816A2 (en) 2004-02-20 2005-02-15 Method of preventing fibrin clots in pulmonary tissue through the use of aerosolized anticoagulants

Publications (1)

Publication Number Publication Date
ATE493135T1 true ATE493135T1 (de) 2011-01-15

Family

ID=34889863

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05713495T ATE493135T1 (de) 2004-02-20 2005-02-15 Verfahren zur verhinderung von fibringerinnseln im lungengewebe durch verwendung von aerosolisierten gerinnungshemmern

Country Status (10)

Country Link
US (2) US20050192226A1 (https=)
EP (2) EP1725244B1 (https=)
JP (2) JP2007533657A (https=)
KR (3) KR20060130661A (https=)
AT (1) ATE493135T1 (https=)
AU (1) AU2005216044B2 (https=)
CA (1) CA2557411A1 (https=)
DE (1) DE602005025610D1 (https=)
IL (1) IL177588A0 (https=)
WO (1) WO2005081816A2 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2480790A1 (en) * 2002-04-01 2003-10-16 Kazunori Murakami Use of antithrombin iii in treating acute lung injury
US20050169908A1 (en) * 2004-01-23 2005-08-04 Kazunori Murakami Use of aerosolized antithrombin to treat acute lung injury
US20050192226A1 (en) * 2004-02-20 2005-09-01 Perenlei Enkhbaatar Method of preventing fibrin clots in pulmonary tissue through the use of aerosolized anticoagulants
US20050245444A1 (en) * 2004-04-30 2005-11-03 Yann Echelard Method of using recombinant human antithrombin for neurocognitive disorders
US20060121004A1 (en) * 2004-12-07 2006-06-08 Yann Echelard Methods of reducing the incidence of rejection in tissue transplantation through the use of recombinant human antithrombin
ES2811526T3 (es) 2010-12-30 2021-03-12 Lab Francais Du Fractionnement Glicoles como agentes de inactivación de patógenos
WO2014089327A1 (en) * 2012-12-05 2014-06-12 National Jewish Health Treatment for airway cast obstruction
EP3594230A1 (en) 2013-02-13 2020-01-15 Laboratoire Français du Fractionnement et des Biotechnologies Highly galactosylated anti-tnf-alpha antibodies and uses thereof
US10034921B2 (en) 2013-02-13 2018-07-31 Laboratoire Français Du Fractionnement Et Des Biotechnologies Proteins with modified glycosylation and methods of production thereof
EP3016729B1 (fr) 2013-07-05 2020-03-25 Laboratoire Francais du Fractionnement et des Biotechnologies Societe Anonyme Matrice de chromatographie d'affinité
FR3038517B1 (fr) 2015-07-06 2020-02-28 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Utilisation de fragments fc modifies en immunotherapie

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6127347A (en) * 1994-01-12 2000-10-03 Univ Michigan Non-anticoagulant chemically modified heparinoids for treating hypovolemic shock and related shock syndromes
US6355626B1 (en) * 1994-05-13 2002-03-12 The Trustees Of The University Of Pennsylvania Antithrombin agents in treatment of asthma
US5843705A (en) * 1995-02-21 1998-12-01 Genzyme Transgenic Corporation Transgenically produced antithrombin III
US7045585B2 (en) * 1995-11-30 2006-05-16 Hamilton Civic Hospital Research Development Inc. Methods of coating a device using anti-thrombin heparin
US6063593A (en) * 1996-11-12 2000-05-16 University Of Southern California University Park Campus TGFβ1 responsive bone marrow derived cells to express a recombinant protein
US6124257A (en) * 1997-08-28 2000-09-26 Lezdey; John Method of treatment
AU2440802A (en) * 2000-10-18 2002-04-29 Massachusetts Inst Technology Methods and products related to pulmonary delivery of polysaccharides
DE10132307A1 (de) 2001-07-06 2003-01-30 Aventis Behring Gmbh Arzneizubereitung zur Inhalation von Antithrombin bei entzündlichen Lungenerkrankungen und ARDS
CA2480790A1 (en) * 2002-04-01 2003-10-16 Kazunori Murakami Use of antithrombin iii in treating acute lung injury
US20050169908A1 (en) * 2004-01-23 2005-08-04 Kazunori Murakami Use of aerosolized antithrombin to treat acute lung injury
US20050192226A1 (en) * 2004-02-20 2005-09-01 Perenlei Enkhbaatar Method of preventing fibrin clots in pulmonary tissue through the use of aerosolized anticoagulants

Also Published As

Publication number Publication date
WO2005081816A3 (en) 2007-02-01
EP1725244A4 (en) 2009-08-12
KR20060130661A (ko) 2006-12-19
EP1725244B1 (en) 2010-12-29
DE602005025610D1 (de) 2011-02-10
WO2005081816A2 (en) 2005-09-09
US20110070167A1 (en) 2011-03-24
US20050192226A1 (en) 2005-09-01
JP2007533657A (ja) 2007-11-22
EP2322189A2 (en) 2011-05-18
KR20100017971A (ko) 2010-02-16
KR20110084555A (ko) 2011-07-25
AU2005216044A1 (en) 2005-09-09
JP2011162555A (ja) 2011-08-25
AU2005216044B2 (en) 2011-07-14
CA2557411A1 (en) 2005-09-09
EP1725244A2 (en) 2006-11-29
IL177588A0 (en) 2008-03-20
EP2322189A3 (en) 2011-07-27

Similar Documents

Publication Publication Date Title
ATE493135T1 (de) Verfahren zur verhinderung von fibringerinnseln im lungengewebe durch verwendung von aerosolisierten gerinnungshemmern
WO2003092602A3 (en) Novel tissue factor targeted thrombomodulin fusion proteins as anticoagulants
DE69229858D1 (de) Methode zur behandlung von entzündungen der lunge
CY1117571T1 (el) Συνδυασμος αντιχολινεργικων και ανταγωνιστων υποδοχεα λευκοτριενιου για την αγωγη αναπνευστικων νοσηματων
DE602006016058D1 (de) Vorrichtungen zur Behandlung von empfänglicher Plaque
CY1110519T1 (el) Συνδυασμος r,r-γλυκοπυρρολικου, ρολιπραμης και βουδεσονιδης για την αντιμετωπιση φλεγμονωδων νοσων
ES2116325T3 (es) Nuevos inhibidores de la trombina.
ATE274345T1 (de) Verfahren zur herstellung einer stabilen mikronisierten zusammensetzung von formoterol mit einem glucocorticosteroid
WO2006121980A3 (en) Apparatus and techniques for reducing the effects of general anesthetics
CU23794B7 (es) Inhibidores macrocíclicos de la replicación del virus de la hepatitis c
CY1107696T1 (el) Συνδιασμος εταβονικης λοτεπρεδνολης και dfho για την αντιμετωπιση αναπνευστικων παθησεων, αλλεργικων παθησεων, ασθματος και copd
TR201820051T4 (tr) Anti-faktör XI Antikorlarının Trombüs Oluşumunun Engellenmesi Veya Tedavisi İçin Kullanılması
ATE521357T1 (de) Verfahren zur behandlung von hepatitis
WO2010071894A3 (en) Tfpi inhibitors and methods of use
WO2008127654A3 (en) Methods and compositions for intra-articular coagulation proteins
BR0011273A (pt) Uracilas de heteroarila e arila policìclica substituìdas como agentes anti-coagulantes
WO2005086915A3 (en) Treatment of chronic obstructive pulmonary disease by low dose inhalation of protease inhibitor
WO2005072139A3 (en) Use of aerosolized antithrombin to treat acute lung injury
ATE425340T1 (de) Eckverbinder für auf gehrung geschnittene hohlprofile von fenstern oder türen
WO2003084476A3 (en) Treatment of lung disorder
MXPA03011702A (es) Composicion que comprende un inhibidor de fosodiesterasa 4 y un antagonista de receptor h1 y el uso de los mismos para la elaboracion de un medicamento para el tratamiento de enfermedades respiratorias.
ATE410147T1 (de) Verwendung von glykosaminglykanen wie z.b. heparin zur behandlung von atemerkrankungen wie copd
ATE444754T1 (de) Verwendung von tyrosinkinase-inhibitoren zur behandlung inflammatorischer prozesse
WO2006026998A8 (en) Methods for treating local tracheal, bronchial or alveolar bleeding or hemoptysis
BG106748A (en) Method and compositions for treating pulmonary diseases

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties